- Home
- HOLO vs LGVN Comparison
HOLO vs LGVN Comparison
Compare HOLO & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- LGVN
- Stock Information
- Founded
- HOLO 2018
- LGVN 2014
- Country
- HOLO China
- LGVN United States
- Employees
- HOLO N/A
- LGVN N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- HOLO Technology
- LGVN Health Care
- Exchange
- HOLO Nasdaq
- LGVN Nasdaq
- Market Cap
- HOLO 95.5M
- LGVN 25.9M
- IPO Year
- HOLO N/A
- LGVN 2021
- Fundamental
- Price
- HOLO $4.47
- LGVN $2.09
- Analyst Decision
- HOLO
- LGVN Strong Buy
- Analyst Count
- HOLO 0
- LGVN 2
- Target Price
- HOLO N/A
- LGVN $8.00
- AVG Volume (30 Days)
- HOLO 5.0M
- LGVN 393.6K
- Earning Date
- HOLO 10-29-2024
- LGVN 11-08-2024
- Dividend Yield
- HOLO N/A
- LGVN N/A
- EPS Growth
- HOLO N/A
- LGVN N/A
- EPS
- HOLO N/A
- LGVN N/A
- Revenue
- HOLO $32,242,196.00
- LGVN $1,229,000.00
- Revenue This Year
- HOLO N/A
- LGVN $161.78
- Revenue Next Year
- HOLO N/A
- LGVN $8.62
- P/E Ratio
- HOLO N/A
- LGVN N/A
- Revenue Growth
- HOLO 326.95
- LGVN 39.34
- 52 Week Low
- HOLO $4.00
- LGVN $0.77
- 52 Week High
- HOLO $1,968.00
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- HOLO 41.41
- LGVN 54.70
- Support Level
- HOLO $4.83
- LGVN $1.76
- Resistance Level
- HOLO $6.01
- LGVN $2.26
- Average True Range (ATR)
- HOLO 0.92
- LGVN 0.12
- MACD
- HOLO -0.05
- LGVN 0.05
- Stochastic Oscillator
- HOLO 4.86
- LGVN 66.00
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.